I awaken to a new world every day. : )
This looks good long term for ENTA, and it makes me wonder if they will hit those upper tiered payments sooner.
The fact that ENTA can break into the entire spectrum of fibrosis, 1a's and 1b's included, all covered seems to open things up a lot more than what Friday approval suggested.
*Some* downside, is that with discounts/rebates/incentives (which we do not know) the price of TX may be lower, but from what I can see.... the package treatment price is higher than expected and a large group of patients have been acquired.
A lot of uncertainty is gone.
I also wonder..... if they already have a roster of patients pre-approved and loaded. We may see a near immediate number of prescriptions, and in decent numbers.....
Lots of the theoretical will soon be gone. They should be posting numbers soon.
